NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

BioVie Inc. (BIVI) Stock Analysis

BioVie Inc. (BIVI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BIVI

$1.26

+$0.02 (+1.61%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BIVI with… →

BIVI Key Statistics

As of Oct 21, 2026
Trading
Open
$1.21
Previous Close
$1.24
Day's Range
1.15–1.28
52-Week Range
0.82–3.79
Volume
194.47K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.73
Valuation
Market Cap
$10.07M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.05
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$17.54M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
8.68M
1-Year Return
−34.03%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
4.59M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BIVI closed at $1.26, −34.03% over 1 year.

BioVie Inc. (BIVI) has a market capitalization of $10.07M.

In fiscal 2025, BIVI reported revenue of $0.00.

BIVI Stock Return by Calendar Year

BioVie Inc. (BIVI) return since Sep 2020: what $10,000 became

1 year
$10,000 $6,597
−34.03%
5 years
$10,000 $22
−99.78%
Since Sep 2020
$10,000 $13
−99.87%

If you had invested $10,000 in BioVie Inc. (BIVI) at the close on September 18, 2020, the earliest close on record here, it would have been worth $13 at the close on October 21, 2026: −99.87% in total, −66.59% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+8.62%
2025−94.20%
2024−84.13%
2023−83.78%
2022+72.67%
2021−74.02%
2020 (partial year)+73.37%

As of October 21, 2026.

BIVI Revenue and Earnings by Fiscal Year

FY ends June
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$17.54M—
2024$0.00−$32.12M—
2023$0.00−$50.26M—
2022$0.00−$26.08M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$18.07M−$17.54M—
2024$0.00—−$32.18M−$32.12M—
2023$0.00—−$45.08M−$50.26M—
2022$0.00—−$27.25M−$26.08M—

Annual figures as reported, in the company's reporting currency. As of June 30, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

BioVie Inc. (BIVI) carries a market capitalisation of $10.07M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 13 employees.

Over the past 52 weeks the price has ranged from $0.82 to $3.79. BIVI last closed at $1.26 on October 21, 2026. That is +$0.02 (+1.61%) against the previous close. The latest close sits 53.66% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $17.54M. Earnings per share on a trailing basis come to −3.05.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is −34.03%. Across 5 years the annualized return works out at −70.55%. The reported beta is 0.73. Annualized volatility over the trailing 6 years is 134.13%.

Growth & Income

No dividend is on file for BIVI.

2026 is still running; the total return is +8.62% year to date. Across the complete calendar years on file, 2022 returned +72.67% and 2025 returned −94.20%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

BioVie Inc. (BIVI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
BioVie Inc. BIVI $10.07M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. BioVie Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About BioVie Inc.

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Visit website →